12:14 PM
Aug 22, 2017
 |  BC Innovations  |  Distillery Therapeutics


INDICATION: Breast cancer

Patient sample, cell culture and mouse studies suggest inhibiting MCL1 could help treat triple-negative breast cancer (TNBC) and HER2-amplified breast cancer. In breast cancer patient samples, levels of MCL1 were higher in TNBC and HER2-amplified tumors than in estrogen receptor 1 (ESR1)-positive tumors. In two human TNBC cell lines and a human HER2-amplified breast cancer cell line, a MCL1...

Read the full 300 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >